Inhaled β2-adrenergic agonists are the most commonly used medications for the treatment of asthma although there is evidence that regular use may produce adverse effects in some patients. Polymorphisms of the β2-adrenergic receptor (β2-AR) can affect regulation of the receptor. Smaller studies examining the effects of such polymorphisms on the response to β-agonist therapy have produced inconsistent results. We examined whether polymorphisms at codon 16 (β2-AR-16) and codon 27 (β2-AR-27) of the β2-AR might affect the response to regular versus as-needed use of albuterol by genotyping the 190 asthmatics who had participated in a trial examining the effects of regular versus as-needed albuterol use. During the 16-wk treatment period there was a small decline in morning peak expiratory flow in patients homozygous for arginine at β2-AR-16 (Arg/Arg) who used albuterol regularly. This effect was magnified during a 4-wk run out period, during which all patients returned to using as-needed albuterol, so that by the end of the study Arg Arg patients who had regularly used albuterol had a morning peak expiratory flow 30.5 ± 12.1 L/min lower (p = 0.012) than Arg/Arg patients who had used albuterol on an as-needed basis. There was no decline in peak flow in regular users of albuterol in patients who were homozygous for glycine at β2-AR-16. Even though a significant effect also declined in the Arg/Arg patients who used albuterol regularly but not in those who used albuterol on an as-needed basis. No significant differences in outcomes between regular and as-needed treatment were associated with polymorphisms at position 27 of the β2-AR. No other differences in asthma outcomes that we investigated occurred in relation to these β2-AR polymorphisms. Polymorphisms of the β2-AR may influence airway responses to regular inhaled β-agonist treatment.

Inhaled selective β2-agonists with an intermediate duration of action are the most commonly prescribed asthma medications in the world (1). Treatment of asthma by inhalation of agents such as albuterol, isethetharine, metaproterenol, pirbuterol, and terbutaline provides immediate and effective reversal of airway obstruction, with marked improvement in symptoms. Over the past several years, there has been considerable controversy about the role of inhaled β-agonists in the treatment of asthma (2–7). Specifically, it has been suggested that the regularly scheduled use of inhaled β-agonists is associated with a deleterious effect on asthma control.

We recently addressed this issue in patients with mild asthma by comparing, in a multicenter, placebo-controlled double-blind trial, asthma control in two cohorts, each of more than 125 patients (8). One cohort was treated with inhaled albuterol on a regularly scheduled basis, two puffs four times a day; the other was treated with an identical appearing inhaled placebo given on the same schedule. We found no clinically significant differences in overall asthma control between the two groups as a whole, despite the fact that the group allocated to regularly scheduled albuterol treatment used, on average, 7.2 puffs a day of inhaled albuterol whereas the as-needed only treatment group used only approximately 1.4 puffs per day. We concluded that, in patients with mild asthma, the regularly scheduled use of inhaled albuterol was not associated with either beneficial or deleterious effects.

While the above trial was in progress a number of polymorphisms of the β2-adrenergic receptor (β2-A R) were identified (9). Studies using mutagenesis and recombinant expression in cells (10, 11) and transgenic mice (12), and using airway smooth muscle cells endogenously expressing these β2-AR variants (13), have shown that some forms of the β2-AR display distinct differences in signaling and/or regulation after chronic exposure to β-agonists. It could thus be possible that these polymorphisms might explain altered pharmacologic responses to β-agonist treatment. In fact, recent studies have suggested that these polymorphisms may be associated with asthma of differing severity (14, 15). Further, other studies have reported a relationship between these polymorphisms and the degree of responsiveness or desensitization to the bronchodilator effect of β-agonists (16–19). However, these studies have produced inconsistent results. A litered desensitization to β-agonists has alternately been associated with either arginine or glycine polymorphisms at the 16 position of the β2-A R and in other cases with polymorphisms at the 27 position. M any of these studies have been short-term, and several of these studies have compared asthmatics of differing severity in whom etiologic heterogeneity may influence apparent associations.

We therefore genotyped the subjects who participated in our earlier trial. We stratified the treatment cohorts and outcome measures with respect to genotype for the β2-A R polymorphisms that occur most commonly in the population. Our data indicate that differences in β2-A R genotypes are associated with altered responses to the regular use of albuterol.

(Received in original form July 21, 1999 and in revised form December 16, 1999)
Supported by NIH Grants U10 HL 51831, U10 HL 51834, U10 HL 51843, U10 HL 51810, U10 HL 51823, U10 HL 51845, R01 HL 45967 and P01 HL 41496.
Correspondence and requests for reprints should be addressed to Elliot Israel, M.D., Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115.
Am J Respir Crit Care Med Vol 162. pp 75–80, 2000
Internet address: www.atsjournals.org
METHODS

Inhaled b-Agonist Trial

The subjects in this report were participants in the National Heart, Lung, and Blood Institute (NHLBI) Asthma Clinical Research Network Trial on the effects of regular versus intermittent use of inhaled b-agonists (8). Two well-matched cohorts of patients with mild asthma (FEV1 > 70% of predicted, provocative concentration of methacholine causing a 20% reduction in FEV1 [PC20] < 8 mg/ml) and inhaled b-agonists (the only asthma treatment) were recruited at five centers across the United States. The patients were randomized to receive regular (two puffs 4 times a day) plus as-needed albuterol or as-needed albuterol alone, in a double-blind manner. The predetermined primary outcome variable for this study was morning (A.M.) peak expiratory flow. A didITIONAL monitoring included evening (P.M.) peak expiratory flow, peak expiratory flow variability, asthma symptom scores, the number of inhalations of rescue albuterol used, FEV1, bronchodilation induced by the inhaled albuterol, and the masked by the bronchodilation induced by the inhaled albuterol.

We found no differences in A.M. peak expiratory flow between the group treated regularly with albuterol and the group receiving intermittent albuterol, despite the fact that on average the regular treatment group used 7.2 puffs a day of albuterol whereas the as-needed group used only 1.3 puffs a day. There were no clinically significant differences between the groups in other physiologic or clinical variables monitored during the study. We concluded that, in patients with mild asthma, the regularly scheduled use of albuterol was not associated with either beneficial or adverse effects.

However, there were some patients who experienced a deterioration in peak expiratory flow during the study. At the end of the trial, we contacted all participants who had been randomized and collected either blood or buccal brushing to obtain cellular material for genotyping. Patients who could not return to their clinical center were mailed cheek brushes to use and to return to the laboratory by mail.

Genotyping was performed by individuals unaware of the results from the clinical trial. Genomic DNA was prepared for genotyping analysis by standard techniques (21). Genotypes at the B16 and B27 position were assessed by the amplification refractory mutation system (ARM S) (22, 23) similar to that previously described (14). Genotype was assigned in approximately 10% of individuals by oligonucleotide-specific hybridization as a quality control measure throughout the study.

RESULTS

Genotypes

Material for genotyping was obtained from 190 of the 255 subjects in the trial. At the B16 and B27 loci, a definite genotype could be assigned in 179 and 177 individuals, respectively. The distribution of patients for whom genotypic information was obtained is shown in Table 1. The allele frequency of B16-A arginine and glycine was 0.6 and 0.4, respectively, and of B27-Glu and Glu 0.6 and 0.4, respectively. The number of individuals possessing each of the potential genotypes at each locus individually (B16 or B27) was consistent with the Hardy-Weinberg equilibrium. A total of 173 individuals were successfully genotyped at both loci. The distribution of the various combinations of heterozygous and homozygous polymorphisms at positions 16 and 27 is shown in Table 2. It is interesting that all individuals with the B16-A arginine is the only genotype that had the B27-Glu/Glu genotype.

Results Stratified by Genotype

There were no significant differences in the baseline characteristics when we stratified our subjects by genotype (Table 3). We examined the effects of regular versus as-needed albuterol use over the 20 wk from the time of randomization through the end of the run-out, stratified by genotype (see METHODS). In B16-A arginine patients, but not in any of the patients with alternate genotypes, regular b-agonist use was associated with a decline in the primary outcome indicator—A.M. peak expiratory flow, and a decline in the secondary outcome indicator—P.M. peak expiratory flow (Table 4). These changes did not occur in any of the other B16 genotypes or any of the B27 genotypes (Table 4). In B16-A arginine patients, regular b-agonist treatment produced a fall in A.M. peak expiratory flow whereas as-needed treatment produced a slight rise in peak expiratory flow (Figure 1). In these patients, the difference in the change

### Table 1

| Treatment Group | B16 | B27 |
|-----------------|-----|-----|
| Regularly scheduled Rx | 126 | 96  |
| As-needed Rx | 129 | 83  |

Definition of abbreviation: Rx = treatment.

### Table 2

| Genotype | B16 | B27 | Treatment Group |
|----------|-----|-----|-----------------|
| Arg/Arg | 26  | 16  | 10  |
| Arg/Gly | 29  | 15  | 14  |
| Gly/Gly | 7   | 3   | 4   |
| Arg/Arg | 0   | 0   | 0   |
| Arg/Gly | 58  | 29  | 29  |
| Gly/Gly | 27  | 15  | 12  |
| Arg/Arg | 0   | 0   | 0   |
| Arg/Gly | 0   | 0   | 0   |
| Gly/Gly | 26  | 16  | 10  |

Total | 173 | 94  | 79  |

Definition of abbreviations: Arg = arginine; Gln = glutamine; Glu = glutamic acid; Gly = glycine.
The patterns of change were similar for the secondary outcome indicator, P.M. peak expiratory flow (Figure 2, Table 4). The P.M. peak expiratory flows of B16-Arg/Gly subjects who received regular treatment fell 31.1 ± 13.0 L/min compared with those B16-Arg/Gly subjects who received as-needed treatment only (p = 0.0167). Once again, the effect of regular treatment occurred only in those with the B16-Arg/Gly genotype. B16-Gly/Gly patients who received regular β-agonist treatment did not experience a drop in mean P.M. peak expiratory flow, and their P.M. peak expiratory flow was 31.6 ± 10.2 L/min greater than that of the B16-Gly/Gly patients who received as-needed treatment (p = 0.012, Figure 1).

**TABLE 3**

| BASELINE CHARACTERISTICS OF SUBJECTS BY GENOTYPE* |
|-----------------------------------------------|

| Characteristic | B16 | B27 |
|----------------|-----|-----|
| **B16**        |     |     |
| Male sex, n (%) |     |     |
| Arg/Arg (n = 28) | 11 (39.3) | 12 (41.3) |
| Arg/Gly (n = 89) | 45 (50.6) | 46 (51.6) |
| Gly/Gly (n = 62) | 20 (32.3) | 18 (29.0) |
| **B27**        |     |     |
| Gin/Gln (n = 62) | 24 (38.7) | 31 (49.4) |
| Gin/Glu (n = 87) | 27 (43.6) | 21 (24.1) |
| Glu/Glu (n = 28) | 58 (93.6) | 87 (100.0) |

* Values are means ± SD unless otherwise indicated.
† Values represent averages for the sixth (final) week of the run-in period.
‡ Peak flow variability was calculated as (evening peak flow – morning peak flow) / evening peak flow * 100.
§ Asthma symptoms were graded by the patient each day, from 0 for no symptoms to 3 for incapacitating symptoms.
¶ Asthma-specific quality-of-life questionnaires were completed by the patients during clinical-center visits. A score of 1.0 indicates that asthma had no effect on the overall quality of life; a score of 2.0, that the patient’s life was "a little limited" by asthma; a score of 3.0, that there was "some limitation"; and a score of 7.0, that there was "total limitation."
** Geometric mean (Interquartile range).
†† Percentage change in FEV₁ from baseline in response to albuterol inhalation. Data are from Week 4 of the run-in period.
L/min greater than the B16-AArgAArg patients who received regular treatment (p = 0.0019, Figure 2). The decrease in A.M., and P.M. peak expiratory flow in response to regular β-agonist use held true even when the B16 heterozygotes were included with the Gly/Gly homozygotes. When the B16-AArgAArg subjects were compared with all B16-non-AArgAArg subjects as a group (B16-AArgGly and B16-Gly/Gly), the A.M. peak expiratory flow difference was 26.6 ± 8.6 (p = 0.0019) L/min and the P.M. peak expiratory flow difference 30.6 ± 9.2 L/min (p = 0.0009) (data not shown). The A.M. and P.M. peak expiratory flow differences also held true when these differences were expressed as a percent of predicted peak expiratory flow and represented a 7% difference owing to regular β-agonist use (Table 4).

There were no clinically significant B16 genotype-related differences in any of the other secondary outcome indices monitored. With respect to the B27 locus, there were no significant differences between individuals harboring each of the genotypes in any of the outcomes monitored. There were also no differences in asthma exacerbations and treatment failures among genotypes by treatment (Fisher exact test).

DISCUSSION

In this report, using a large cohort of well characterized, mild asthmatics (190 patients), we demonstrate that regular use of β-agonists can produce distinct effects on airway function in patients with specific polymorphisms of the β-adrenergic receptor. Regular use, as opposed to as-needed use, reduced both A.M. and P.M. peak expiratory flow in patients homozygous for the AArg16 allele. This deterioration in pulmonary function associated with regular albuterol use was particular to the AArg16 allele because patients homozygous for the Gly16 allele did not experience such an effect. Further, we found that polymorphisms at amino acid 27 of the β-adrenergic receptor did not alter the response to regular β-agonist use in these asthmatic patients.

In vitro studies have demonstrated that B16-AArg and B16-Gly variants of the β-adrenergic receptor do not differ in terms of receptor binding characteristics or receptor-mediated activation of the adenyl cyclase second messenger pathway. However, they do
differ in the extent to which the respective receptors are downregulated in response to long-term catecholamine exposure (10-13). Thus, β2-AR polymorphisms might alter the response to the use of β-agonists. However, the clinical effects and associations noted with β2-AR polymorphisms have been contradictory in nature. Several of the associations have been derived from studies that contained small groups of patients and/or asthmatics who were heterogeneous in terms of disease severity.

We were able to genotype (in a blinded manner) 190 carefully defined patients available from our study of regular versus as-needed β-agonist use and to examine the influence of genotype at the β2-AR on the effect of regular use of albuterol on our predetermined primary outcome variable, A.M. peak expiratory flow. Peak expiratory flow had been chosen as the primary outcome variable for the prior study because it is a well-documented indicator of deteriorating asthma control (26, 27). It is a measurement that was obtained daily from our patients, thus providing a large number of data points for each patient. We performed our primary comparison in homozygous individuals because we believed that heterozygous individuals might have an intermediate phenotype that might have been difficult to define.

We found that regular albuterol use was associated with a decline in A.M. and p.m. peak expiratory flow in patients who are B16-AArg/AArg. These data suggest that patients with the B16-AArg/AArg polymorphism may be at risk for adverse effects, or less of a salutary effect, when using β-agonists regularly. This is of particular importance because many patients with mild asthma will increase the frequency of β-agonist use during asthma exacerbations. Our data suggest that a proportion of these patients (the approximately 15% of patients who are AArg/AArg at B16), may not benefit to the same degree as the general population, when they use their β-agonists regularly and may actually experience a decline in airway function, especially as they discontinue high-dose β-agonist therapy. Whether concomitant inhaled corticosteroids would blunt this adverse effect is unclear. However, more than 70% of patients with asthma use β-agonists as their only form of therapy and will increase β-agonist use with exacerbations.

The A.M. peak expiratory flow difference that occurred in the B16-AArg/AArg patients was greater than 30 L/min. A decline of this magnitude has been associated with significant clinical deteriorations in asthmatics. For example, declines of 19 and 23 L/min in A.M. and p.m. peak expiratory flow, respectively, have been reported in patients taken off inhaled corticosteroids and were associated with clinical deteriorations (28). A 25 L/min difference occurred between asthmatics treated with regular inhaled corticosteroids versus those treated with regular β-agonists in a major study by Haahtela and coworkers (19). It is therefore of interest that we did not observe differences, that varied by genotype, in our secondary outcome variables such as peak flow variability or FVC20.

Previously published studies have suggested that other β-agonist genotypes may be associated with asthma of differing severity or other markers associated with asthma. Patients with nocturnal asthma were more likely to have the B16-Gly form of the receptor (14). B27-Gln has been associated with elevated levels of IgE (30). In another study, B27-Glu has been associated with a lower degree of airway reactivity than B27-Gln (15). In contrast to our study, these studies encompassed a wide range of asthmatics, including moderate to severe asthmatics. Because our patients were all chosen to be mild asthmatics, we did not expect to have a wide enough range of asthmatics to detect relationships related to severity. For instance, in our population, the peak mean peak expiratory flow difference was approximately 7% of the baseline peak expiratory flow and thus may not have been adequate to precipitate appreciable functional changes in this mild population over such a short time period. However, in a more severe population of asthmatics such a decline, if it occurred, might have more profound and more rapid clinical implications. It is thus of interest, that in the slightly more severe population of asthmatics reviewed previously, a worsening of airway reactivity did in fact occur in the B16-AArg homozygotes (18).

It also worth noting that the majority of the decline in peak expiratory flow in the B16-AArg/AArg patients occurred in the run-out, after patients had stopped using their albuterol regularly. We had specifically designed the run-out period of this study because of a concern that the bronchodilating effect of the regular β-agonist use might mask a deleterious effect. The precise mechanism of this postalbuterol deterioration in disease control is unclear. Although rebound effects occur after withdrawal of β-agonists, it is not clear that they are long-lived enough to explain the effect we observed.

Although our study was not designed to explain the mechanism of the decline in airway function that occurred only in the B16-AArg/AArg subjects who used regular albuterol, our knowledge of the properties of the alternate forms of the receptors may explain our findings. B16-Gly expression downregulates to a greater extent than B16-AArg after exposure to catecholamines (11). Taken alone, these data would suggest that tachyphylaxis to the effect of regular exogenous β-agonists would occur to a greater degree with B16-Gly. However, in a proposal of a so-called “dynamic model” of receptor kinetics (20), it has been suggested that endogenous catecholamines actively downregulate the β2-AArg at baseline. Thus, in the resting state, Gly16 (the variant more susceptible to downregulation) would be downregulated to a greater extent than Arg16 and endogenous catecholamines. It then follows that the tachyphylactic effect of regular exogenous exposure to β-agonists would be most apparent in Arg16 patients because their receptors have not yet been downregulated. Further, this dynamic model would predict that the initial response to albuterol would be depressed in individuals with the Gly16 polymorphism, because their receptors have been endogenously downregulated to a greater extent than in patients with the Arg16 polymorphism. The findings of Martinez and coworkers (19) are in concert with this model because they found that B16-AArg/AArg patients have an enhanced bronchodilator response to albuterol. In contrast, reports in two much smaller studies have found decreased responses, or greater degrees of tachyphylaxis, associated with Gly16 or Gln27 (16, 17). However, the latter study involved the β-agonist formoterol, which has unique interactions with the β-receptor. Our findings of a lack of effect of genotypic variants at the B-27 locus are also consistent with the in vitro studies. Whereas B27-Gln has a greater tendency to downregulation than B27-Glu, these effects are overcome by the downregulation phenotype at B16.

Although the effects we observed are consistent with the effects predicted by the dynamic model for the AArg/AArg genotype at position 16, we cannot rule out the possibility that the mechanism of this effect may be totally unrelated to the downregulation of the receptors. Rather, it is possible that the B16-AArg genotype is in linkage disequilibrium with a polymorphism nearby on the genome. For example, the AArg16 polymorphism has recently been shown to be in linkage disequilibrium with a polymorphism at the S' leader cistron, which is 102 base pairs upstream of the β2-AArg coding block and codes for a peptide that influences the translation of the β2-AArg gene (31). While this specific polymorphism is also in linkage disequilibrium with Gln27 as well, making it unlikely to be the source of the association we observed, other polymorphisms may yet be identified. In this regard, there is a linkage between B16-AArg and B27-Gln so that haplotypically all patients who are B16-AArg possess B27-Gln (see Table 2). A n analysis of the sub-
group of patients who were B27-GlN/Gln showed that the adverse effect of regular use of β-agonists was still attributable to the A rg/A rg genotype (data not shown). Regardless of the mechanism of the effect, the association we observed suggests that the A rg16 polymorphism, at the very least, clinically serves as a marker for an altered pharmacologic response to β-agonists.

In summary, we have demonstrated that the homozygous arginine genotype at position 16 of the β2-A R can influence the response to use of a β-agonist. The altered response in these patients occurs only with regular use, as compared with as-needed use. Most asthmatics, whether using concomitant anti-inflammatory therapy or not, increase their β-agonist use during exacerbations. Approximately 15% of the population is homozygous for A rg16. If corroborated, our findings suggest that these individuals may benefit by avoiding regularly scheduled β-agonists and might be candidates for earlier intervention with anti-inflammatory agents.

Acknowledgment: The authors gratefully acknowledge the assistance of Lisa Atkin in preparing the manuscript for publication and Erik Lehman for performing additional statistical analyses.

References

1. Nelson, H. S. 1995. Beta-adrenergic bronchodilators. N. Engl. J. Med. 333: 499–506.
2. Sears, M. R., D. R. Taylor, C. G. Print, D. C. Lake, Q. Q. Li, E. M. Flannery, D. M. Y. ates, K. M. Lucas, and G. P. Herbisón. 1990. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 336:1391–1396.
3. Pearlman, D. S., P. Chervinsky, C. LaForce, J. M. Seltzer, D. L. South- ern, J. P. Kemppainen, R. F. Liddle, and S. W. Y. aney. 1992. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N. Engl. J. Med. 327:1420–1425.
4. Chapman, K. R., S. Kesten, and J. P. Szalai. 1994. Regular vs as-needed inhaled salbutamol in asthma control. Lancet 343:1379–1382.
5. McFadden, E. R., J. R. 1995. Perspectives in beta 2-agonist therapy: vox clamantis in desertO velux in tenebris? J. Allergy Clin. Immunol. 95: 641–651.
6. Sears, M. R. 1995. Is the routine use of inhaled beta-adrenergic agonists appropriate in asthma treatment? No. Am. J. Respir. Crit. Care Med. 151:600–611.
7. Wanner, A. 1995. Is the routine use of inhaled beta-adrenergic agonists appropriate in asthma treatment? Yes. Am. J. Respir. Crit. Care Med. 151:597–599.
8. Drazen, J. M., E. Israel, H. A. Bouhey, V. M. Chinchilli, J. V. Fahy, J. E. Fish, S. C. Lazarus, R. F. Lemanske, J. R. M.artin, S. P. Peters, C. Sorkness, and J. S. Szelzer, for the National Heart, Lung, and Blood Institute’s Asthma Clinical Research Network. 1996. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. N. Engl. J. Med. 335:841–847.
9. Reilhau, E., M. Inns, N. Meacintyre, and S. B. Liggett. 1993. Mutations in the gene encoding for the β2-adrenergic receptor in normal and asthmatic subjects. Am. J. Respir. Crit. Care Med. 151:597–599.
10. Green, S. A., G. Cole, M. Jacinto, M. Inns, and S. B. Liggett. 1993. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J. Biol. Chem. 268:23116–23121.
11. Green, S. A., J. Turki, M. Inns, and S. B. Liggett. 1994. A mini-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 33:9414–9419.
12. Turki, J., J. N. Lorenz, S. A. Green, E. T. D. Donnelly, M. Jacinto, and S. B. Liggett. 1996. M yocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 93:10483–10488.
13. Green, S. A., J. Turki, P. Bjarajano, J. P. Hall, and S. B. Liggett. 1995. Influence of beta(2)-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 13:25–33.
14. Turki, J., J. Pak, S. A. Green, R. J. Martin, and S. B. Liggett. 1995. Polymorphisms of the beta 2-adrenergic receptor in nocturnal and non‐nocturnal asthma: evidence that Gly16 correlates with the nocturnal phenotype. J. Clin. Investig. 95:1635–1641.
15. Hall, I. P., A. Wheatley, P. Widling, and S. B. Liggett. 1995. A association of Glu 27 beta 2-adrenergic receptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet 345:1213–1214.
16. Ohe, M., M. M. Unakata, N. Hizawa, A. Ittoh, I. Doi, E. Y. amaguchi, Y. Homma, and Y. K. awakami. 1995. Beta 2 adrenergic receptor gene restriction fragment length polymorphism and bronchial asthma. Thorax 50:353–359.
17. Tan, S., I. P. Hall, J. Dower, E. D. Dow, and B. Lipworth. 1997. A association between beta2-adrenergic receptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 350:995–999.
18. Hancox, R. J., M. R. Sears, and D. R. Taylor. 1998. Polymorphism of the beta 2-adrenergic receptor and the response to long-term beta 2-agonist therapy in asthma. Eur. Respir. J. 11:589–593.
19. Martínez, D. F., P. E. Graves, M. Baldini, S. Solomon, and R. Erickson. 1997. A association between genetic polymorphisms of the beta 2-adrenergic receptor and response to albuterol in children with and without a history of wheezing. J. Clin. Investig. 100:3184–3188.
20. Liggett, S. B. 1997. Polymorphisms of the beta 2-adrenergic receptor and asthma. A m. J. Respir. Crit. Care Med. 156(Suppl. 1):S156–S162.
21. Maniatis, T., E. F. Fritsch, and J. Sambrook. 1982. Molecular Cloning: A Laboratory Manual anual, Cold Spring Harbor Laboratory, New York.
22. Newton, C. R., L. E. Heptinstall, C. Summers, M. Super, M. Schwarz, R. A. nwar, A. Graham, J. C. Smith, and A. F. M arkhaim. 1989. A mplification refractory mutation system for prenatal diagnosis and carrier assessment in cystic fibrosis. Lancet 2:1481–1483.
23. Newton, C. R., A. Graham, L. E. Heptinstall, S. J. Powell, C. Summers, N. A. shelke, J. C. Smith, and A. F. M arkhaim. 1989. A nalysis of an point mutation in D NA: the amplification refractory mutation system (ARMS). Nucleic Acids Res. 17:2503–2516.
24. Vonesh, E. F., and R. L. Carter. 1987. Efficient inference for random-coefficient growth curve models with unbalanced data. Biometrics 43:617–628.
25. Laird, N. M., C. Donnelly, and J. H. Ware. 1982. Longitudinal studies with continuous responses. Stat. Methods Med. Res. 1:225–247.
26. National Asthma Education Program. 1997. Guidelines for the Diagnosis and Treatment of Asthma II. National Institutes of Health, Bethesda, MD.
27. National Heart Lung and Blood Institute. 1995. NHLBI/WHO Workshop Report: Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma. National Heart, Lung, and Blood Institute, Bethesda, MD. Publication No. 95-3659.
28. Chervinsky, P., A. van As, E. A. Brosny, R. Dockhorn, M. Noonan, C. LaForce, and W. Pleskow. 1994. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J. Allergy Clin. Immunol. 94:676–683.
29. Haahlt, E., T. J. A. vinen, T. Kava, K. K. ivant, S. K. oskinen, K. Lhtonen, K. N. ikander, T. Persson, K. R. ikainen, O. S. roos, et al. 1991. C omparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N. Engl. J. Med. 325:388–392.
30. Dewar, J. C., J. Wilkinson, A. Wheatley, N. S. Thomas, I. Doull, N. Mor- ton, P. Lio, J. F. Harvey, S. B. Liggett, S. T. Olgate, and I. P. Hall. 1997. The glutatione 2 beta 2-adrenergic receptor polymorphism is associated with elevated IgE levels in astmatic families. J. Allergy Clin. Immunol. 100:261–265.
31. McGraw, D., D. R. Forbes, L. A. Kramer, and S. B. Liggett. 1998. Polymorphisms of the S leader cistron of the human beta 2-adrenergic receptor regulate receptor expression. J. Clin. Investig. 102:1972–1932.

APPENDIX

Additional Asthma Clinical Research Network Investigators: J. D. Spanh, National Jewish Medical and Research Center, Denver, CO; T. J. Craig, and E. A. Mauger, Milton S. Hershey Medical Center, Hershey, PA; S. A. Nuchman, The Harlem Hospital Center, New York, NY; C. V. Chambers, K. R. Epstein, and S. J. McGeady, Thomas Jefferson University, Philadelphia, PA.